Cargando…

Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis

The study aimed to evaluate the prognostic value of CD169 expression in tumor-infiltrating macrophages from regional lymph nodes (RLN) in various tumors. In order to identify eligible articles, PubMed, EMBASE, Web of Science, and Cochrane Library were used to conduct a systematic search. Pooled haza...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Weihao, Wei, Meng, Liu, Rongqiang, Zhang, Jianlin, Wang, Xingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806965/
https://www.ncbi.nlm.nih.gov/pubmed/34607536
http://dx.doi.org/10.1080/21655979.2021.1985857
_version_ 1784643585053818880
author Kong, Weihao
Wei, Meng
Liu, Rongqiang
Zhang, Jianlin
Wang, Xingyu
author_facet Kong, Weihao
Wei, Meng
Liu, Rongqiang
Zhang, Jianlin
Wang, Xingyu
author_sort Kong, Weihao
collection PubMed
description The study aimed to evaluate the prognostic value of CD169 expression in tumor-infiltrating macrophages from regional lymph nodes (RLN) in various tumors. In order to identify eligible articles, PubMed, EMBASE, Web of Science, and Cochrane Library were used to conduct a systematic search. Pooled hazard ratios (HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were adopted to assess the relationship between CD169 expression and overall survival (OS) and clinicopathological characteristics. Ten studies, including eleven cohorts with 1699 patients, were enrolled. We found that high CD169(+) expression in tumor-infiltrating macrophages from RLN was associated with a favorable OS (HR = 0.56, 95%CI: 0.39–0.79, P = 0.001). Subgroup analysis showed that high CD169+ expression had more predictive power in digestive system tumors (HR = 0.52, 95%CI: 0.42–0.67, <0.001). In addition, high CD169 expression was significantly linked with lymph node metastasis (OR = 0.66, 95%CI: 0.47–0.94, P = 0.020) and TNM stage (OR = 0.62, 95%CI: 0.48–0.80, P < 0.001). High CD169 expression in tumor-infiltrating macrophages from RLN was correlated with favorable survival outcome in patients with malignancies. CD169 may be a novel and effective prognostic marker, especially for digestive system tumors.
format Online
Article
Text
id pubmed-8806965
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88069652022-02-02 Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis Kong, Weihao Wei, Meng Liu, Rongqiang Zhang, Jianlin Wang, Xingyu Bioengineered Reviews The study aimed to evaluate the prognostic value of CD169 expression in tumor-infiltrating macrophages from regional lymph nodes (RLN) in various tumors. In order to identify eligible articles, PubMed, EMBASE, Web of Science, and Cochrane Library were used to conduct a systematic search. Pooled hazard ratios (HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were adopted to assess the relationship between CD169 expression and overall survival (OS) and clinicopathological characteristics. Ten studies, including eleven cohorts with 1699 patients, were enrolled. We found that high CD169(+) expression in tumor-infiltrating macrophages from RLN was associated with a favorable OS (HR = 0.56, 95%CI: 0.39–0.79, P = 0.001). Subgroup analysis showed that high CD169+ expression had more predictive power in digestive system tumors (HR = 0.52, 95%CI: 0.42–0.67, <0.001). In addition, high CD169 expression was significantly linked with lymph node metastasis (OR = 0.66, 95%CI: 0.47–0.94, P = 0.020) and TNM stage (OR = 0.62, 95%CI: 0.48–0.80, P < 0.001). High CD169 expression in tumor-infiltrating macrophages from RLN was correlated with favorable survival outcome in patients with malignancies. CD169 may be a novel and effective prognostic marker, especially for digestive system tumors. Taylor & Francis 2021-10-22 /pmc/articles/PMC8806965/ /pubmed/34607536 http://dx.doi.org/10.1080/21655979.2021.1985857 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Kong, Weihao
Wei, Meng
Liu, Rongqiang
Zhang, Jianlin
Wang, Xingyu
Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis
title Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis
title_full Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis
title_fullStr Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis
title_full_unstemmed Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis
title_short Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis
title_sort prognostic value of cd169-positive macrophages in various tumors: a meta-analysis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806965/
https://www.ncbi.nlm.nih.gov/pubmed/34607536
http://dx.doi.org/10.1080/21655979.2021.1985857
work_keys_str_mv AT kongweihao prognosticvalueofcd169positivemacrophagesinvarioustumorsametaanalysis
AT weimeng prognosticvalueofcd169positivemacrophagesinvarioustumorsametaanalysis
AT liurongqiang prognosticvalueofcd169positivemacrophagesinvarioustumorsametaanalysis
AT zhangjianlin prognosticvalueofcd169positivemacrophagesinvarioustumorsametaanalysis
AT wangxingyu prognosticvalueofcd169positivemacrophagesinvarioustumorsametaanalysis